SARS-CoV-2 appeared in Switzerland in February 2020 and reached Neuchâtel in March During 2 months, 43 patients were admitted in the intensive care unit 55% of ICU admitted patients received mechanical ventilation, 66% of which in prone position All patients were treated with hydroxychloroquine The majority of patients received antiretrovirals One patient was treated with remdesivir Near half the patients were treated with tocilizumab One patient received a convalescent plasma obtained from patients who had recovered from COVID-19 The mortality rate was 17% These results are in line with those from university intensive care units in Switzerland
[Intensive care unit treatment for patients suffering from COVID-19: the Neuchâtel experience]